Coloplast A/S
CSE:COLO B
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
748.4
976
|
| Price Target |
|
We'll email you a reminder when the closing price reaches DKK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Coloplast A/S
Coloplast A/S
Total Liabilities & Equity
Coloplast A/S
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Coloplast A/S
CSE:COLO B
|
Total Liabilities & Equity
kr48.1B
|
CAGR 3-Years
45%
|
CAGR 5-Years
30%
|
CAGR 10-Years
N/A
|
|
Coloplast A/S
Glance View
Coloplast A/S is a leading global healthcare company headquartered in Denmark, dedicated to the development of innovative medical devices and solutions for individuals with intimate healthcare needs. Founded in 1954, the company has a strong heritage built on empathy and understanding of patient challenges, which drives its continuous commitment to enhancing the quality of life for people with chronic conditions. Coloplast operates in three primary business areas: ostomy care, urology, and continence care, crafting products that empower individuals to manage their health effectively. With a presence in over 40 countries and products sold in more than 100 markets, Coloplast not only boasts a robust portfolio but also demonstrates significant global reach, setting itself apart in a competitive healthcare landscape. For investors, Coloplast presents an attractive opportunity characterized by its steady revenue growth and focus on innovation. The company has implemented a patient-centric approach, which not only fosters brand loyalty but also supports resilience in market fluctuations. With a solid track record of investing in research and development, Coloplast continually enhances its product offerings, ensuring that it remains a trusted partner for patients and healthcare providers alike. As societal trends shift towards personalized and home-based care, Coloplast's strategic initiatives aim to capitalize on these changes, making it well-positioned for sustainable growth in the long term. This strong foundation, marked by operational excellence and a commitment to corporate social responsibility, underscores Coloplast's potential to deliver both solid financial returns and positive societal impact.
See Also
What is Coloplast A/S's Total Liabilities & Equity?
Total Liabilities & Equity
48.1B
DKK
Based on the financial report for Sep 30, 2024, Coloplast A/S's Total Liabilities & Equity amounts to 48.1B DKK.
What is Coloplast A/S's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
30%
Over the last year, the Total Liabilities & Equity growth was 0%. The average annual Total Liabilities & Equity growth rates for Coloplast A/S have been 45% over the past three years , 30% over the past five years .
You don't have any saved screeners yet
